Partners Group acquires Pharmathen from BC Partners. The advisors

Switzerland-based global private markets firm, Partners Group, has, on behalf of its clients, agreed to acquire Pharmathen, a Greece-based pharmaceutical company, from international U.S. based investment firm BC Partners. The transaction values Pharmathen at an enterprise value of around EUR 1.6 billion. The deal, which is subject to receipt of customary regulatory approvals, is expected to close in 2021.

As per the press release by Partners Group, Partners Group will work closely with Pharmathen’s management team, led by CEO Dimitris Kadis, on initiatives to scale the business in Europe and globally, aiming to specifically accelerate the expansion in the US.

The advisors

For Partners Group Holding, Swiss-based in-house general counsel Andreas Knecht (pictured) acted as legal counsel alongside U.S. based Ropes & Gray law firm. EY acted as accountants on this transaction.

For BC Partners, U.S. based in-house general counsel Jason Schaefer acted as legal counsel alongside Kirkland & Ellis law firm. Jefferies acted as financial advisors while Pwc provided accounting advice and services.

Partners Group

Partners Group is a global private markets firm established in 1996. since inception, the firm has invested over USD 150 billion in private equity, private real estate, private debt and private infrastructure on behalf of its clients globally, with more than USD 5 billion of that in health & life companies. The firm employs more than 1,500 persons across 20 offices worldwide and has regional headquarters in Baar-Zug, Switzerland; Denver, USA; and Singapore. It has been listed on the SIX Swiss Exchange since 2006 (symbol: PGHN).

For further details on the deal click here